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Abstract
Background: Vitamin D deficiency in women diagnosed with polycystic ovary syndrome (PCOS) remarkably
decreases the chance of pregnancy, which might be related to its impact on metabolic abnormalities in these
patients. It is hypothesized that vitamin D supplementation influences metabolic profile of these patients and
indirectly might affect fertility and the outcomes. Therefore, this study was conducted to determine the effects of vitamin
D supplementation on the levels of anti-Müllerian hormone (AMH), metabolic profiles, and gene expression of insulin and
lipid metabolism in infertile women with PCOS who were candidate for in vitro fertilization (IVF).
Methods: This study was a randomized, double-blinded, placebo-controlled trial conducted among 40 infertile women,
aged 18–40 years, diagnosed with PCOS and was candidate for IVF. Participants were randomly assigned into
two intervention groups for receiving either 50,000 IU vitamin D or placebo (n = 20 each group) every other
week for 8 weeks. Gene expression for insulin and lipid metabolism was conducted using peripheral blood
mononuclear cells (PBMCs) of women with PCOS, via RT-PCR method.
Results: Vitamin D supplementation led to a significant reduction in serum AMH (− 0.7 ± 1.2 vs. − 0.1 ± 0.5 ng/mL,
P = 0.02), insulin levels (− 1.4 ± 1.6 vs. -0.3 ± 0.9 μIU/mL, P = 0.007), homeostatic model of assessment for insulin
resistance (− 0.3 ± 0.3 vs. -0.1 ± 0.2, P = 0.008), and a significant increase in quantitative insulin sensitivity check
index (+ 0.009 ± 0.01 vs. + 0.001 ± 0.004, P = 0.04), compared with the placebo. Moreover, following vitamin D
supplementation there was a significant decrease in serum total- (− 5.1 ± 12.6 vs. + 2.9 ± 10.9 mg/dL, P = 0.03) and
LDL-cholesterol levels (− 4.5 ± 10.3 vs. + 2.5 ± 10.6 mg/dL, P = 0.04) compared with the placebo.
Conclusion: Overall, the findings of this trial supported that 50,000 IU vitamin D supplementation every other
week for 8 weeks had beneficial effects on insulin metabolism, and lipid profile of infertile women with PCOS
who are candidate for IVF. These benefits might not be evident upon having sufficient vitamin D levels.
Trial registration: This study was retrospectively registered in the Iranian website (www.irct.ir) for clinical trials
registration (http://www.irct.ir: IRCT20170513033941N27).
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Background
Polycystic ovary syndrome (PCOS) is one of the most com-
mon endocrine disorders among women affecting 4% to
12% of women in reproductive age [1]. It is a multifactorial
syndrome presented with obesity, insulin resistance, dyslip-
idemia and other metabolic abnormalities. Obesity leads to
more than 70% insulin resistance in these patients [2]. Insu-
lin resistance, occurs in patients with PCOS, is significantly
associated with different metabolic abnormalities including
elevated aromatase activity, increased androgen production,
and impaired progesterone synthesis in granulosa cells [2].
Current evidence has reported a high risk of metabolic dis-
orders predisposing individuals to cardiovascular disease
(CVD) in in vitro fertilization (IVF) pregnancies [3, 4] and
animal models [5, 6]. However, the independent role of in-
sulin resistance in in vitro fertilization (IVF) outcomes is
less defined in the literature [7].
There is a significant association between serum vita-
min D levels and reproductive function, already reported
in murine models [8]. Further, studies investigating the
role of vitamin D receptor (VDR) in reproductive tissues
have supported a positive correlation between vitamin D
status and reproduction [9]. VDR is located in different
reproductive tissues including ovary (particularly granu-
losa cells), uterus, placenta and testis [10]. Diverse ex-
pression of VDR suggests a potential role of vitamin D
in female reproductive function [11]. Moreover, in
PCOS, ovarian physiology is influenced by the metabolic
disorders observed in these patients; therefore, a
beneficial effect of vitamin D on metabolic abnormalities
might translate into an ideal ovarian physiology [12, 13].
Vitamin D supplementation is recommended as a poten-
tial therapeutic adjunct for the ovulatory dysfunction
and metabolic disorders observed in women with PCOS
[14, 15]. Evidence evaluating the impact of vitamin D de-
ficiency on the success rate of reproduction following
IVF in humans is limited [16, 17]. Moreover, vitamin D
deficiency is correlated with poor ovarian stimulation in
PCOS but not unexplained infertility [18]. Likewise, vita-
min D has been shown to be involved in a minor path-
way related to metabolic and hormonal dysregulation in
women with PCOS [19]. Therefore, the beneficial effects
of vitamin D on the metabolic disorders in PCOS might
translate into an improvement in ovarian physiology.
The majority of current studies investigating the effects
of vitamin D supplementation on metabolic status in pa-
tients with PCOS have not specifically looked into IVF.
And to our best knowledge, this trial is the first study
assessing the effects of vitamin D supplementation on
glycemic control, markers of cardiometabolic risk and
gene expression of insulin and lipid metabolism in infer-
tile women diagnosed with PCOS who were candidate
for IVF. In a study conducted by Seyyed Abootorabi et
al. [20] vitamin D supplementation at a dosage of
50,000 IU/week for 8 weeks reduced fasting glucose and
increased adiponectin levels in women diagnosed with
PCOS who were vitamin D deficient. Further, in a
meta-analysis performed by Xue et al. [21], vitamin D
administration to patients with PCOS significantly de-
creased triglycerides levels, while did not change insulin
metabolism and other markers of lipid profiles. On
the other hand, recently there are concerns about the
risks associated to uncontrolled vitamin D supple-
mentation [22].
Current evidence and the physiological role of vitamin
D in reproductive activity might support the significance
of vitamin D supplementation while doing IVF in infer-
tile women with PCOS F. So, this study was aimed to
determine the effects of vitamin D supplementation on
glycemic control, markers of cardiometabolic abnormal-
ities and gene expression of insulin and lipid metabolism
in infertile women diagnosed with PCOS and candidate
for IVF.
Methods
Trial design and participants’ characteristics
This study was a randomized, double-blinded, placebo-
controlled trial conducted on 40 infertile women, aged
18 to 40 years old, with PCOS, diagnosed using Rotter-
dam criteria [23], who were candidate for IVF. The study
was registered in the Iranian website for clinical trials
registration (http://www.irct.ir: IRCT20170513033941N2
7). Recruited participants were referred patients at
Research and Clinical Center for Infertility and Naghavi
Clinic, Kashan, Iran, from December 2017 through
March 2018. Any case of metabolic disorders, including
thyroid disorder, diabetes or impaired glucose tolerance
was excluded at screening phase. This study was
performed following Declaration of Helsinki and was
approved by the research ethics committee of Kashan
University of Medical Sciences (KAUMS). Written
informed consent was signed by all subjects prior to the
intervention.
Intervention
Participants were randomly assigned into two interven-
tion groups to receive either 50,000 IU vitamin D (n =
20) or placebo (n = 20) every other week for 8 weeks.
Vitamin D and placebo (paraffin) capsules were simi-
larly matched in color, shape, size and packaging, and
were manufactured by Zahravi (Tabriz, Iran) and Barij
Essence (Kashan, Iran), respectively. Random number
table was used for randomization by one of the re-
searchers not involved in other processes of trial.
Randomization and allocation were concealed from the
investigators and study participants until the comple-
tion of analyses. Compliance rate was assessed through
measuring serum 25(OH)D levels and asking patients
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to return back the medication containers. To increase
the compliance, all subjects were received a short mes-
sage on their cell phones every day, throughout the
trial, to take the supplements.
Assessment of outcomes
Insulin metabolism was considered as the primary out-
come. Lipid profiles and gene expression of insulin and
lipid metabolism were defined as the secondary out-
comes. Fifteen milliliter fasting blood was collected at
the beginning and end of the trial at Naghavi Clinic la-
boratory, Kashan, Iran. Fasting plasma glucose (FPG)
concentrations were measured on the day of blood col-
lection, using enzymatic kits with the coefficient vari-
ances (CVs) of less than 5%. Serum 25-hydroxyvitamin
D (25 (OH) D) concentrations were determined by an
ELISA kit (IDS, Boldon, UK) with inter- and intra-assay
CVs of lower than 7%. Serum AMH levels were
measured using an ELISA kit (Bioactiva, Homburg,
Germany) with CVs of lower than 6%. Serum insulin con-
centrations were measured by an ELISA kit (DiaMetra, Mi-
lano, Italy) with inter- and intra-assay CVs of 3.5 and 5.0%,
respectively. The homeostasis model of assessment-insulin
resistance (HOMA-IR) and the quantitative insulin sensi-
tivity check index (QUICKI) were determined according to
the published formula [24]. Enzymatic kits (Pars Azmun,
Tehran, Iran) were applied to measure serum lipid profiles
with inter- and intra-assay of less than 5%.
Isolation of lymphocyte cells
Blood samples were used to extract lymphocyte cells,
using 50% percoll (Sigma-Aldrich, Dorset, UK). Cell
count and viability test were performed using trypan
blue, RNA and DNA extraction [25].
RNA extraction and real-time PCR (RT-PCR)
RNA was extracted from blood samples using RNX-plus
kit (Cinnacolon, Tehran, Iran). RNA suspension was fro-
zen at − 20 °C until cDNA was derived. RNA quantifica-
tion was conducted using UV spectrophotometer and
total RNAs were extracted from each sample. Each sam-
ple OD 260/280 ratio was considered to range from 1.7
to 2.1, representing no contamination with either pro-
tein or DNA [25].
The isolated RNA was reverse transcribed to cDNA
library, using moloney murine leukemia virus reverse
transcriptase (RT). Gene expressions of peroxisome
proliferator-activated receptor gamma (PPAR-γ), glu-
cose transporter 1 (GLUT-1) and low-density lipopro-
tein receptor (LDLR) were done using peripheral blood
mononuclear cells (PBMCs) via SYBR green detection
and Amplicon Kit, applying quantitative RT-PCR and
Light Cycler technology (Roche Diagnostics, Rotkreuz,
Switzerland) (Table 1). Glyceraldehyde-3-phosphate
dehydrogenase (GAPDH) primers were used as a
housekeeping gene. Primers were designed using
Primer Express Software (Applied Biosystems, Foster
City, USA) and Beacon designer software (Takaposizt,
Tehran, Iran). Relative transcription levels were calcu-
lated using Pffafi or 2-ΔΔCT methods [25].
Sample size
Clinical trial sample size formula was used to calculate
sample size considering a type one error (α) of 0.05 and
type two error (β) of 0.20 with the power of 80%. Mean
difference (d) of HOMA-IR equal to 0.8 and SD of 0.8
were used for the calculation [26]. Sample size was de-
fined as 16 participants in each group. Considering 4
probable dropouts in each group, the final sample size
was determined to be 20 participants in each group.
Statistical methods
Kolmogorov-Smirnov test was used to assess the normal
distribution of variables. Analyses were replicated using
intention-to-treat (ITT) approach. To determine the dif-
ferences in anthropometric measures and gene expres-
sion of insulin and lipid metabolism between the
intervention groups, we used independent samples t-test.
The effects of vitamin D supplementation on glycemic
control and markers of cardiometabolic risk were
assessed using repeated measures ANOVA test. The
P-values of < 0.05 were considered statistically signifi-
cant. Statistical analyses were conducted using the Stat-
istical Package for Social Science version 18 (SPSS Inc.,
Chicago, Illinois, USA).
Results
We had three dropouts in each intervention group due
to personal reasons, and 34 participants [infertile women
with PCOS candidate for IVF receiving vitamin D (n =
17) and placebo (n = 17)] completed the study (Fig. 1).
Using ITT protocol, all 40 participants (20 in each
group) were included in the final analysis. Compliance
rate in this trial ranged 90% to100% in both groups. No
side effects were reported following vitamin D supple-
mentation in infertile women with PCOS who were can-
didate for IVF throughout the study. Mean age, height,
weight and BMI were not statistically different between
the intervention groups throughout the trial (Table 2).
After 8-week intervention, vitamin D supplementation
led to a significant reduction in serum AMH (− 0.7 ± 1.2
vs. -0.1 ± 0.5 ng/mL, P = 0.02) and insulin levels (− 1.4 ±
1.6 vs. -0.3 ± 0.9 μIU/mL, P = 0.007), HOMA-IR (− 0.3 ±
0.3 vs. -0.1 ± 0.2, P = 0.008), as well as a significant in-
crease in QUICKI (+ 0.009 ± 0.01 vs. + 0.001 ± 0.004, P =
0.04) compared with placebo (Table 3). Further, taking
vitamin D supplements significantly decreased serum
total- (− 5.1 ± 12.6 vs. + 2.9 ± 10.9 mg/dL, P = 0.03) and
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LDL-cholesterol levels (− 4.5 ± 10.3 vs. + 2.5 ± 10.6 mg/
dL, P = 0.04) compared with the placebo. There was no
significant effect of vitamin D supplementation on fast-
ing glucose and other parameters of lipid profiles.
RT-PCR quantitative tests showed a significant upreg-
ulation of gene expression of PPAR-γ (P = 0.01), GLUT-
1 (P = 0.009) and LDLR (P = 0.03) in PBMCs of infertile
women diagnosed with PCOS who were candidate for
IVF following vitamin D supplementation rather than
placebo (Fig. 2).
Discussion
The results of this trial demonstrated the beneficial ef-
fects of 50,000 IU vitamin D supplementation every
other week for 8 weeks on improving insulin metabolism
and some of the markers of lipid profile among infertile
women diagnosed with PCOS who were candidate for
IVF. These benefits might not be evident upon having
sufficient vitamin D levels. To our best knowledge, this
study has reported the effects of vitamin D supplemen-
tation on AMH, glycemic control, lipid profiles and gene
expression of insulin and lipid metabolism in infertile
women for the first time.
Polycystic ovary syndrome predisposes patients to differ-
ent metabolic abnormalities, such as insulin resistance and
dyslipidemia [27, 28]. This study demonstrated that
50,000 IU vitamin D supplementation every other week for
8 weeks resulted in significant decreases in serum AMH,
insulin levels and HOMA-IR score, and a significant in-
crease in QUICKI in infertile women with PCOS who were
Table 1 Specific primers used for real-time quantitative PCR
Gene Primer Product size (bp) Annealing temperature ©
GAPDH F: AAGCTCATTTCCTGGTATGACAACG 126 61.3
R: TCTTCCTCTTGTGCTCTTGCTGG
PPAR-γ F: ATGACAGACCTCAGACAGATTG 210 54
R: AATGTTGGCAGTGGCTCAG
GLUT-1 F: TATCTGAGCATCGTGGCCAT 238 62.1
R: AAGACGTAGGGACCACACAG
LDLR F: ACTTACGGACAGACAGACAG 223 57
R: GGCCACACATCCCATGATTC
GAPDH glyceraldehyde-3-Phosphate dehydrogenase, GLUT-1 glucose transporter 1, LDLR low-density lipoprotein receptor, PPAR-γ peroxisome proliferator-activated
receptor gamma
Randomized (n=40)
Allocated to placebo (n=20)
Lost to follow-up (n=3)
Analyzed (n=20)
Allocated to intervention (n=20)
Lost to follow-up (n=3)
Analyzed (n=20)
Assessed for eligibility (n=7)
Excluded (n=7) 
- Not meeting inclusion criteria (n=7) 
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Fig. 1 Summary of patient flow diagram
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candidate for IVF. Further, vitamin D supplementation sig-
nificantly increased gene expression levels of PPAR-γ and
GLUT-1. In the agreement with our study, Gupta et al. [29]
demonstrated that vitamin D supplementation at a dosage
of 60,000 IU weekly for 12 weeks significantly reduced in-
sulin levels and HOMA-IR, and significantly increased
QUICKI in vitamin D-deficient women with PCOS. In an-
other study, taking vitamin D supplements at a dosage of
20,000 IU per week for 24 weeks by women with PCOS,
having serum calcium levels < 2.65 mmol/L and uncertain
serum 25 (OH) D status at baseline, improved glucose me-
tabolism and menstrual frequency [30]. However, there are
also studies with discrepant findings. Garg et al. [31],
showed that vitamin D supplementation at a dose of
4000 IU/day for 6 months to vitamin D-deficient women
with PCOS did not have any significant effect on insulin re-
sistance and insulin secretion. Insulin resistance is associ-
ated with increased synthesis of vasoconstriction factors,
which might be the reason for vascular stiffness in women
diagnosed with PCOS [32]. Therefore, improved insulin
metabolism by vitamin D supplementation may decrease
the risk of metabolic complications subsequent to insulin
resistance in these patients. The mechanisms involved in
the impact of vitamin D on insulin metabolism could be
direct and indirect effects of vitamin D on stimulating
insulin release through improved vitamin D receptor ex-
pression, enhancing insulin sensitivity for glucose transpor-
tation and suppressing the release of pro-inflammatory
cytokines [33].
We found that 50,000 IU vitamin D supplementation
every other week for 8 weeks significantly decreased total-
and LDL-cholesterol levels in infertile women with PCOS
who were candidate for IVF, compared with the placebo,
though other lipid profiles parameters remained unchanged.
Moreover, vitamin D supplementation significantly increased
gene expression levels of LDLR. Similar to our findings,
vitamin D supplementation at a dosage of 4000 IU/day
for 12 weeks significantly decreased total cholesterol
Table 2 General characteristics of study participants
Placebo group (n = 20) Vitamin D group (n = 20) Pa
Age (y) 30.1 ± 3.4 29.9 ± 4.4 0.87
Height (cm) 159.2 ± 2.0 160.4 ± 3.3 0.16
Weight at study baseline (kg) 72.0 ± 6.9 71.3 ± 9.9 0.77
Weight at end-of-trial (kg) 72.2 ± 6.8 71.5 ± 9.6 0.79
Weight change (kg) 0.1 ± 0.8 0.2 ± 0.9 0.70
BMI at study baseline (kg/m2) 28.4 ± 2.6 27.7 ± 3.9 0.49
BMI at end-of-trial (kg/m2) 28.5 ± 2.6 27.8 ± 3.7 0.50
BMI change (kg/m2) 0.1 ± 0.3 0.1 ± 0.3 0.68
Data are means± SDs
a Obtained from independent t-test
Table 3 Glycemic control, markers of cardio-metabolic risk and oxidative stress at baseline and after the 8-week intervention in
infertile polycystic ovary syndrome women candidate for in vitro fertilization that received either vitamin D supplements or placebo
Placebo group (n = 20) Vitamin D group (n = 20) Pa
Baseline End-of-trial Change Baseline End-of-trial Change
Vitamin D (ng/mL) 11.0 ± 2.4 10.9 ± 2.1 -0.1 ± 0.6 10.5 ± 2.5 21.7 ± 5.9 11.2 ± 5.0 < 0.001
AMH (ng/mL) 8.7 ± 2.7 8.6 ± 2.5 -0.1 ± 0.5 7.7 ± 3.4 7.0 ± 3.1 −0.7 ± 1.2 0.02
FPG (mg/dL) 92.9 ± 5.5 93.5 ± 5.6 0.5 ± 3.0 90.3 ± 10.5 89.4 ± 10.6 −0.9 ± 7.4 0.42
Insulin (μIU/mL) 11.4 ± 1.9 11.1 ± 2.0 −0.3 ± 0.9 11.2 ± 2.2 9.8 ± 2.7 −1.4 ± 1.6 0.007
HOMA-IR 2.6 ± 0.5 2.5 ± 0.4 −0.1 ± 0.2 2.5 ± 0.7 2.2 ± 0.7 −0.3 ± 0.3 0.008
QUICKI 0.33 ± 0.008 0.33 ± 0.009 0.001 ± 0.004 0.33 ± 0.01 0.34 ± 0.02 0.009 ± 0.01 0.04
Triglycerides (mg/dL) 111.5 ± 35.5 117.4 ± 34.8 5.9 ± 13.2 105.3 ± 33.5 107.5 ± 38.1 2.1 ± 17.4 0.44
VLDL-cholesterol (mg/dL) 22.3 ± 7.1 23.5 ± 6.9 1.2 ± 2.6 21.1 ± 6.7 21.5 ± 7.6 0.4 ± 3.5 0.44
Total cholesterol (mg/dL) 197.1 ± 36.3 200.0 ± 36.5 2.9 ± 10.9 203.6 ± 26.6 198.5 ± 24.7 −5.1 ± 12.6 0.03
LDL-cholesterol (mg/dL) 124.9 ± 35.9 127.4 ± 35.3 2.5 ± 10.6 133.1 ± 21.1 128.7 ± 20.8 −4.5 ± 10.3 0.04
HDL-cholesterol (mg/dL) 49.9 ± 7.5 49.1 ± 8.2 −0.8 ± 3.9 49.4 ± 5.7 48.4 ± 5.4 −1.0 ± 2.8 0.81
Data are means± SDs
a Obtained from repeated measures ANOVA test
AMH anti-Müllerian hormone, FPG fasting plasma glucose, HOMA-IR homeostasis model of assessment-estimated insulin resistance, QUICKI quantitative insulin
sensitivity check index
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concentrations in vitamin D deficient HIV-infected
patients [34]. In a meta-analysis conducted by Akbari et
al. [35], vitamin D supplementation significantly de-
creased LDL-cholesterol levels in gestational diabetes
patients, though other lipid profiles parameters did not
change. There are also contrary studies demonstrating
that vitamin D supplementation (100,000 IU loading
dose, followed by 20,000 IU/week) did not improve
CVD risk factors including blood pressure, lipid profiles
and glucose metabolism parameters in vitamin D insuf-
ficient population [36]. Current evidence suggested that
increased insulin and androgens levels may negatively
influence lipid profiles in women with PCOS [37]. Fatty
acids byproducts have an important role in inflamma-
tion and reproduction [37]. Improved insulin sensitivity
and decreased production of PTH by vitamin D might
decrease total- and LDL-cholesterol [38]. Further, insu-
lin reduces biosynthesis of cholesterol via increased
3-hydroxy-3-methylglutaryl CoA (HMG-CoA) reduc-
tase activity [39], which in turn decreases total- and
LDL-cholesterol levels.
There are a few limitations in this study. First, the evalu-
ation of insulin resistance in the current study, was only
based on HOMA-IR. We did not assess any direct dynamic
test, such as glucose tolerance test or hyperinsulinemic
euglycemic clamp. Second, some of the insignificant results
might be related to the short duration of intervention. So,
further studies are required with longer duration and higher
sample size to confirm our findings. In addition, all the par-
ticipants were vitamin D deficient, so the observed effects
might be correlated with the correction of vitamin D defi-
ciency, rather than the supplementation per se. This should
be considered in the interpretation of our finding.
Conclusions
Overall, the findings of this trial supported that
50,000 IU vitamin D supplementation every other week
for 8 weeks had beneficial effects on insulin metabolism,
and some parameters of lipid profiles among infertile
women with PCOS who were candidate for IVF. These
benefits might not be evident upon having sufficient
vitamin D levels.
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